BioNTech

BioNTech demonstrated during the COVID-19 pandemic that Europe possesses world-class capability in mRNA platform technology, developing the first widely authorized mRNA vaccine in partnership with Pfizer. Beyond vaccines, the company is advancing a deep pipeline of mRNA-based cancer immunotherapies that could reshape oncology treatment over the coming decade. BioNTech's success validates Europe's capacity to originate and scale breakthrough biomedical technologies rather than depending on US pharmaceutical giants for therapeutic innovation.